| 货号 | 12097-10mg |
| 描述 | Pazopanib is a broad spectrum tyrosine kinase inhibitor that blocks angiogenesis through its actions on VEGF receptors (VEGFRs).1 It has low nanomolar efficacy against VEGFR1 (FLT1), VEGFR2, VEGFR3 (FLT4), and KIT, as well as receptors for macrophage colony-stimulating factor 1 and platelet-derived growth factor.1,2,3 Pazopanib is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 and, to a lesser extent, CYP1A2 and CYP2C8.4 It is effective in vivo and is useful in the management of certain types of cancer.4,5,6 |
| 别名 | GSK-VEG10003;GW786034B;Votrient; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Podar, K.,Tonon, G.,Satler, M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 103(5), 19478-19483 (2006). 2.Davis, M.I.,Hunt, J.P.,Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat.Biotechnol. 29(11), 1046-1051 (2011). 3.Uitdehaag, J.C.M.,de Roos, J.A.D.M.,van Doornmalen, A.M., et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 9(3), 1-13 (2014). 4.van Geel, R.M.J.M.,Beijnen, J.H., and Schellens, J.H.M. Concise drug review: Pazopanib and axitinib. Oncologist 17(8), 1081-1089 (2012). 5.Ulahannan, S.V., and Brahmer, J.R. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Investigation 29(4), 325-337 (2011). 6.Sun, M.,Larcher, A., and Karakiewicz, P.I. Optimal first-line and second-line treatments for metastatic renal cell carcinoma: Current evidence. Int.J.Nephrol.Renovasc.Dis. 7, 401-407 (2014). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 437.5 |
| 分子式 | C21H23N7O2S |
| CAS号 | 444731-52-6 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |